Drug Repurposing Market, By Deployment Mode (On-premises and Cloud-based), By Therapeutic Area, By End Use, By Drug Molecules, By Type of Approach, By Route of Administration, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4717
|
Published Date
February 2026
|
Pages
349
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Drug Repurposing Market size was valued at US$ 33,018.10 Million in 2024, expanding at a CAGR of 4.30% from 2025 to 2032.
The drug repurposing market focuses on identifying new therapeutic applications for existing or previously approved drugs, enabling faster and more cost-effective treatment development compared with traditional drug discovery. Market growth is driven by rising research and development costs and the urgent need to accelerate therapies for complex, rare, and unmet medical conditions. Governments and public research agencies are increasingly supporting these efforts: for example, in February 2024, the United States’ Advanced Research Projects Agency for Health (ARPA-H) awarded USD 48.3 million in funding to support Every Cure’s AI-powered drug repurposing platform aimed at accelerating treatment discovery. Additionally, public institutions globally—to the tune of 36 % of repurposing research funding reported in academic studies—play a pivotal role in advancing repurposing projects. A major trend shaping the market is the growing use of artificial intelligence and real-world data to uncover novel drug–disease relationships and optimize candidate selection. However, regulatory uncertainties, intellectual property constraints, and challenges related to data validation continue to pose significant barriers. Despite these challenges, increasing emphasis on rare diseases, oncology, and emerging infectious diseases presents substantial opportunities for drug repurposing by shortening development timelines, reducing clinical failure risk, and maximizing the therapeutic value of existing pharmaceutical assets.
Drug Repurposing Market- Market Dynamics
Increasing Healthcare Expenditure Fueling Growth in the Drug Repurposing Market
The rising level of global healthcare expenditure is a key driver of growth in the drug repurposing market. Healthcare spending—which encompasses prevention, diagnosis, treatment, rehabilitation, and administration—is increasing due to higher medical costs, technological advancements, and growing demand for healthcare services. This surge in spending enables greater investment in research activities, clinical trials, and data-driven studies, all of which are critical for identifying new therapeutic applications for existing drugs. Drug repurposing benefits from this trend as it provides a faster and more cost-effective alternative to traditional drug discovery. According to the 2021–2030 National Health Expenditure report by the United States Centers for Medicare & Medicaid Services (published in March 2022), national health spending is projected to grow at an average annual rate of 5.1%, reaching nearly USD 6.8 trillion by 2030. Increased Medicare and Medicaid funding further supports drug repurposing research, accelerating market expansion and enabling more rapid development of innovative therapies.
Drug Repurposing Market- Segmentation Analysis:
The global drug repurposing market is segmented by deployment mode, therapeutic area, end use, drug molecules, type of approach, route of administration, and region. Oncology represents a major segment, driven by the high prevalence of cancer worldwide and the urgent need for more effective and affordable therapies. Existing oncology drugs, as well as therapies initially approved for non-cancer indications, are increasingly being evaluated for new oncology applications. Leveraging the established safety and efficacy profiles of these drugs significantly reduces development time and cost, accelerating patient access to innovative treatments. For example, in December 2024, researchers at UT Southwestern reported that an FDA-approved therapy for multiple myeloma and lymphoma showed tumor-shrinking effects in patients with KRAS-mutated non-small cell lung cancer. Global support for cancer innovation further reinforces this trend: the World Health Organization (WHO) estimates that governments spend more than USD 150 billion annually on cancer prevention, treatment, and research worldwide, highlighting the strong institutional backing for repurposing strategies that can accelerate therapeutic options in oncology.
By End Use, pharmaceutical and biotechnology companies capture the majority of the market revenue. These organizations benefit from established R&D infrastructure, regulatory expertise, and financial resources, allowing them to repurpose existing drugs efficiently for new therapeutic indications. The rising demand for affordable therapies and the need to address unmet medical needs further motivate these companies to explore repurposing strategies. A notable example is the repurposing of baricitinib: the U.S. Food and Drug Administration (FDA) approved the drug in May 2022 for hospitalized adults requiring varying degrees of respiratory support due to COVID-19, following an earlier Emergency Use Authorization (EUA) in November 2020 for use in combination with remdesivir. This approval was based on results from the Adaptive COVID-19 Treatment Trial (ACTT-2), which demonstrated shorter recovery times and improved clinical outcomes. Government investment in drug repurposing is rising globally: the OECD reports that over 60 countries have established national pharmaceutical innovation strategies that allocate more than USD 20 billion annually to research programs supporting drug repurposing and accelerated clinical evaluation of existing therapeutics.
Drug Repurposing Market- Geographical Insights
North America currently dominates the drug repurposing market, driven by advanced research infrastructure, supportive regulatory frameworks, and expedited approval processes for repurposed drugs. The region also fosters strong collaborations between AI startups, research institutions, and major pharmaceutical companies to accelerate the development of repurposed therapies across a range of diseases. For instance, in August 2025, Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., partnered with LUNR Aerospace to advance AI-powered drug repurposing initiatives specifically targeting applications in space medicine.
United States Drug Repurposing Market- Country Insights
The United States represents the largest market in North America, supported by a robust pharmaceutical and biotechnology sector that is heavily investing in AI-driven drug discovery platforms. For instance, in September 2025, Massachusetts-based Lila Sciences raised USD 235 million in a Series A funding round to expand its AI-powered autonomous laboratories. The investment will support the growth of Lila’s “AI Science Factories” in Boston, San Francisco, and London, where AI models generate hypotheses, conduct experiments, analyze results, and iterate through the entire research process. The country’s strong financing ecosystem, coupled with well-established collaborations between academic institutions and AI solution providers, continues to drive large-scale drug repurposing initiatives.
Drug Repurposing Market- Competitive Landscape:
The drug repurposing market is characterized by extensive collaborations among pharmaceutical companies, biotech firms, research institutions, and technology providers, all aimed at identifying new therapeutic uses for existing drugs. Strategic partnerships, licensing agreements, and investments in advanced computational platforms that accelerate repurposing research are key factors shaping competition. Companies are increasingly leveraging artificial intelligence, real-world evidence, and big data analytics to enhance target identification, streamline clinical validation, and reduce development costs. Regulatory alignment and shared research frameworks also influence competitive positioning. Leading players such as Novartis AG, Pfizer Inc., Eli Lilly and Company, and Bayer AG are driving innovation and commercial activity in the market, utilizing extensive compound libraries, global R&D capabilities, and strategic alliances to expand their portfolios of repurposed drugs and strengthen market visibility. In April 2025, Novartis announced the acquisition of Regulus Therapeutics, a San Diego-based clinical-stage biopharmaceutical company specializing in microRNA therapies. Regulus’ leading asset, Faburden, targets miR-17 and has the potential to become a first-in-class treatment for autosomal dominant polycystic kidney disease (ADPKD). This acquisition complements Novartis’ focus on renal diseases and enhances its expertise in this therapeutic area, while broadening its portfolio with novel approaches to kidney disease treatment.
Recent Developments:
- In April 2025, Qualthera Health Corporation, focused on creating a nationwide network of patient-centered compounding pharmacies, officially launched Qualthera Pharmaceuticals Ltd. Co., a research-driven subsidiary dedicated to drug repurposing and innovative delivery systems. This expansion leverages real-world patient insights to accelerate the development of new therapies.
- In June 2024, BioXcel Therapeutics applied AI-driven drug repurposing to discover new applications for previously stalled drug candidates. By integrating approved and clinically validated compounds with big data and proprietary machine learning algorithms, the company accelerates therapeutic innovation while addressing R&D costs, market access, and growth opportunities, particularly in neurology and immuno-oncology.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Eli Lilly and Company
- GSK plc
- Amgen Inc.
- Biogen Inc.
- Pfizer Inc.
- Roche Holding AG
- Novartis AG
- AbbVie
- Amgen
- Boehringer Ingelheim
- Cyclica
- GlaxoSmithKline
- Vertex Pharmaceuticals
- Melior Discovery
- Pharnext
- Recursion Pharmaceuticals
- Revolution Medicines
- Sanofi
- Schwarz Pharma
- Valence Discovery
- Bayer AG
- Teva Pharmaceutical
- Others
GLOBAL DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032
- On-premises
- Cloud-based
GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Rare Diseases
- Neurology
- Immunology
- Metabolic Disorders
- Others
GLOBAL DRUG REPURPOSING MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032
- Contract Research Organizations (CROs)
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
- Academic & Research Institutes
- Others
GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES- MARKET ANALYSIS, 2019 - 2032
- Peptides
- Biologics
- Vaccines
- Conventional Small Molecules
- Others
GLOBAL DRUG REPURPOSING MARKET, BY TYPE OF APPROACH- MARKET ANALYSIS, 2019 - 2032
- Target-centric
- Disease-centric
- Drug-centric
GLOBAL DRUG REPURPOSING MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intravenous
- Oral
- Other routes of administration
GLOBAL DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Drug Repurposing Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Drug Repurposing Market Snippet by Deployment Mode
2.1.2. Drug Repurposing Market Snippet by Therapeutic Area
2.1.3. Drug Repurposing Market Snippet by End Use
2.1.4. Drug Repurposing Market Snippet by Drug Molecules
2.1.5. Drug Repurposing Market Snippet by Type of Approach
2.1.6. Drug Repurposing Market Snippet by Route of Administration
2.1.7. Drug Repurposing Market Snippet by Country
2.1.8. Drug Repurposing Market Snippet by Region
2.2. Competitive Insights
3. Drug Repurposing Key Market Trends
3.1. Drug Repurposing Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Drug Repurposing Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Drug Repurposing Market Opportunities
3.4. Drug Repurposing Market Future Trends
4. Drug Repurposing Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Drug Repurposing Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Drug Repurposing Market Landscape
6.1. Drug Repurposing Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Drug Repurposing Market – By Deployment Mode
7.1. Overview
7.1.1. Segment Share Analysis, By Deployment Mode, 2024 & 2032 (%)
7.1.2. On-premises
7.1.3. Cloud-based
8. Drug Repurposing Market – By Therapeutic Area
8.1. Overview
8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
8.1.2. Oncology
8.1.3. Cardiovascular Diseases
8.1.4. Infectious Diseases
8.1.5. Rare Diseases
8.1.6. Neurology
8.1.7. Immunology
8.1.8. Metabolic Disorders
8.1.9. Others
9. Drug Repurposing Market – By End Use
9.1. Overview
9.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
9.1.2. Contract Research Organizations (CROs)
9.1.3. Pharmaceutical & Biotechnology Companies
9.1.4. Healthcare Providers
9.1.5. Academic & Research Institutes
9.1.6. Others
10. Drug Repurposing Market – By Drug Molecules
10.1. Overview
10.1.1. Segment Share Analysis, By Drug Molecules, 2024 & 2032 (%)
10.1.2. Peptides
10.1.3. Biologics
10.1.4. Vaccines
10.1.5. Conventional Small Molecules
10.1.6. Others
11. Drug Repurposing Market – By Type of Approach
11.1. Overview
11.1.1. Segment Share Analysis, By Type of Approach, 2024 & 2032 (%)
11.1.2. Target-centric
11.1.3. Disease-centric
11.1.4. Drug-centric
12. Drug Repurposing Market – By Route of Administration
12.1. Overview
12.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
12.1.2. Intravenous
12.1.3. Oral
12.1.4. Other routes of administration
13. Drug Repurposing Market– By Geography
13.1. Introduction
13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
13.2. North America
13.2.1. Overview
13.2.2. Drug Repurposing Key Manufacturers in North America
13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.2.4. North America Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.2.6. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.2.7. North America Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.2.8. North America Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.2.9. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.2.10. U.S.
13.2.10.1. Overview
13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.2.10.3. U.S. Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.2.10.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.2.10.5. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.2.10.6. U.S. Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.2.10.7. U.S. Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.2.10.8. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.2.11. Canada
13.2.11.1. Overview
13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.2.11.3. Canada Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.2.11.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.2.11.5. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.2.11.6. Canada Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.2.11.7. Canada Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.2.11.8. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3. Europe
13.3.1. Overview
13.3.2. Drug Repurposing Key Manufacturers in Europe
13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.3.4. Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.6. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.7. Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.8. Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.9. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.10. Germany
13.3.10.1. Overview
13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.10.3. Germany Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.10.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.10.5. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.10.6. Germany Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.10.7. Germany Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.10.8. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.11. UK
13.3.11.1. Overview
13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.11.3. UK Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.11.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.11.5. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.11.6. UK Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.11.7. UK Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.11.8. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.12. France
13.3.12.1. Overview
13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.12.3. France Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.12.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.12.5. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.12.6. France Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.12.7. France Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.12.8. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.13. Italy
13.3.13.1. Overview
13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.13.3. Italy Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.13.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.13.5. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.13.6. Italy Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.13.7. Italy Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.13.8. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.14. Spain
13.3.14.1. Overview
13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.14.3. Spain Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.14.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.14.5. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.14.6. Spain Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.14.7. Spain Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.14.8. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.15. The Netherlands
13.3.15.1. Overview
13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.15.3. The Netherlands Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.15.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.15.5. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.15.6. The Netherlands Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.15.7. The Netherlands Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.15.8. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.16. Sweden
13.3.16.1. Overview
13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.16.3. Sweden Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.16.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.16.5. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.16.6. Sweden Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.16.7. Sweden Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.16.8. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.17. Russia
13.3.17.1. Overview
13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.17.3. Russia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.17.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.17.5. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.17.6. Russia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.17.7. Russia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.17.8. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.18. Poland
13.3.18.1. Overview
13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.18.3. Poland Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.18.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.18.5. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.18.6. Poland Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.18.7. Poland Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.18.8. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.19. Rest of Europe
13.3.19.1. Overview
13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.19.3. Rest of the Europe Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.3.19.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.3.19.5. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.3.19.6. Rest of the Europe Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.3.19.7. Rest of the Europe Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.3.19.8. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4. Asia Pacific (APAC)
13.4.1. Overview
13.4.2. Drug Repurposing Key Manufacturers in Asia Pacific
13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.4.4. APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.6. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.7. APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.8. APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.9. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.10. China
13.4.10.1. Overview
13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.10.3. China Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.10.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.10.5. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.10.6. China Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.10.7. China Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.10.8. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.11. India
13.4.11.1. Overview
13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.11.3. India Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.11.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.11.5. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.11.6. India Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.11.7. India Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.11.8. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.12. Japan
13.4.12.1. Overview
13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.12.3. Japan Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.12.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.12.5. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.12.6. Japan Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.12.7. Japan Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.12.8. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.13. South Korea
13.4.13.1. Overview
13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.13.3. South Korea Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.13.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.13.5. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.13.6. South Korea Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.13.7. South Korea Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.13.8. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.14. Australia
13.4.14.1. Overview
13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.14.3. Australia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.14.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.14.5. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.14.6. Australia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.14.7. Australia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.14.8. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.15. Indonesia
13.4.15.1. Overview
13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.15.3. Indonesia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.15.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.15.5. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.15.6. Indonesia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.15.7. Indonesia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.15.8. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.16. Thailand
13.4.16.1. Overview
13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.16.3. Thailand Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.16.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.16.5. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.16.6. Thailand Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.16.7. Thailand Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.16.8. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.17. Philippines
13.4.17.1. Overview
13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.17.3. Philippines Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.17.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.17.5. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.17.6. Philippines Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.17.7. Philippines Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.17.8. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.18. Rest of APAC
13.4.18.1. Overview
13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.18.3. Rest of APAC Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.4.18.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.4.18.5. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.4.18.6. Rest of APAC Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.4.18.7. Rest of APAC Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.4.18.8. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5. Latin America (LATAM)
13.5.1. Overview
13.5.2. Drug Repurposing Key Manufacturers in Latin America
13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.5.4. LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.5.6. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.5.7. LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.5.8. LATAM Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.5.9. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.10. Brazil
13.5.10.1. Overview
13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.10.3. Brazil Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.5.10.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.5.10.5. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.5.10.6. Brazil Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.5.10.7. Brazil Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.5.10.8. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.11. Mexico
13.5.11.1. Overview
13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.11.3. Mexico Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.5.11.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.5.11.5. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.5.11.6. Mexico Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.5.11.7. Mexico Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.5.11.8. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.12. Argentina
13.5.12.1. Overview
13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.12.3. Argentina Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.5.12.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.5.12.5. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.5.12.6. Argentina Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.5.12.7. Argentina Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.5.12.8. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.13. Colombia
13.5.13.1. Overview
13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.13.3. Colombia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.5.13.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.5.13.5. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.5.13.6. Colombia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.5.13.7. Colombia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.5.13.8. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.14. Rest of LATAM
13.5.14.1. Overview
13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.14.3. Rest of LATAM Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.5.14.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.5.14.5. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.5.14.6. Rest of LATAM Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.5.14.7. Rest of LATAM Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.5.14.8. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6. Middle East and Africa
13.6.1. Overview
13.6.2. Drug Repurposing Key Manufacturers in Middle East and Africa
13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.6.4. Middle East and Africa Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.6. Middle East and Africa Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.7. Middle East and Africa Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.8. Middle East and Africa Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.9. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.10. Saudi Arabia
13.6.10.1. Overview
13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.10.3. Saudi Arabia Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.10.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.10.5. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.10.6. Saudi Arabia Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.10.7. Saudi Arabia Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.10.8. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.11. United Arab Emirates
13.6.11.1. Overview
13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.11.3. United Arab Emirates Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.11.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.11.5. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.11.6. United Arab Emirates Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.11.7. United Arab Emirates Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.11.8. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.12. Israel
13.6.12.1. Overview
13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.12.3. Israel Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.12.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.12.5. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.12.6. Israel Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.12.7. Israel Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.12.8. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.13. Turkey
13.6.13.1. Overview
13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.13.3. Turkey Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.13.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.13.5. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.13.6. Turkey Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.13.7. Turkey Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.13.8. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.14. Algeria
13.6.14.1. Overview
13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.14.3. Algeria Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.14.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.14.5. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.14.6. Algeria Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.14.7. Algeria Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.14.8. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.15. Egypt
13.6.15.1. Overview
13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.15.3. Egypt Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.15.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.15.5. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.15.6. Egypt Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.15.7. Egypt Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.15.8. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.16. Rest of MEA
13.6.16.1. Overview
13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.16.3. Rest of MEA Market Size and Forecast, By Deployment Mode, 2019 - 2032 (US$ Million)
13.6.16.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
13.6.16.5. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
13.6.16.6. Rest of MEA Market Size and Forecast, By Drug Molecules, 2019 - 2032 (US$ Million)
13.6.16.7. Rest of MEA Market Size and Forecast, By Type of Approach, 2019 - 2032 (US$ Million)
13.6.16.8. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
14. Key Vendor Analysis- Drug Repurposing Industry
14.1. Competitive Benchmarking
14.1.1. Competitive Dashboard
14.1.2. Competitive Positioning
14.2. Company Profiles
14.2.1. Eli Lilly and Company
14.2.2. GSK plc
14.2.3. Amgen Inc.
14.2.4. Biogen Inc.
14.2.5. Pfizer Inc.
14.2.6. Roche Holding AG
14.2.7. Novartis AG
14.2.8. AbbVie
14.2.9. Amgen
14.2.10. Boehringer Ingelheim
14.2.11. Cyclica
14.2.12. GlaxoSmithKline
14.2.13. Vertex Pharmaceuticals
14.2.14. Melior Discovery
14.2.15. Pharnext
14.2.16. Recursion Pharmaceuticals
14.2.17. Revolution Medicines
14.2.18. Sanofi
14.2.19. Schwarz Pharma
14.2.20. Valence Discovery
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL DRUG REPURPOSING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Eli Lilly and Company
- GSK plc
- Amgen Inc.
- Biogen Inc.
- Pfizer Inc.
- Roche Holding AG
- Novartis AG
- AbbVie
- Amgen
- Boehringer Ingelheim
- Cyclica
- GlaxoSmithKline
- Vertex Pharmaceuticals
- Melior Discovery
- Pharnext
- Recursion Pharmaceuticals
- Revolution Medicines
- Sanofi
- Schwarz Pharma
- Valence Discovery
- Bayer AG
- Teva Pharmaceutical
- Others
GLOBAL DRUG REPURPOSING MARKET, BY DEPLOYMENT MODE- MARKET ANALYSIS, 2019 - 2032
- On-premises
- Cloud-based
GLOBAL DRUG REPURPOSING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Rare Diseases
- Neurology
- Immunology
- Metabolic Disorders
- Others
GLOBAL DRUG REPURPOSING MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032
- Contract Research Organizations (CROs)
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
- Academic & Research Institutes
- Others
GLOBAL DRUG REPURPOSING MARKET, BY DRUG MOLECULES- MARKET ANALYSIS, 2019 - 2032
- Peptides
- Biologics
- Vaccines
- Conventional Small Molecules
- Others
GLOBAL DRUG REPURPOSING MARKET, BY TYPE OF APPROACH- MARKET ANALYSIS, 2019 - 2032
- Target-centric
- Disease-centric
- Drug-centric
GLOBAL DRUG REPURPOSING MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intravenous
- Oral
- Other routes of administration
GLOBAL DRUG REPURPOSING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
CONTACT INFORMATION
Email:
U.S. Office
11923 NE Sumner St STE 750924
Portland, Oregon, 97220, USA
Asia Pacific Office
4, Rohan Business Centre, Paud Road,
Kothrud, Pune Maharashtra, 411038, India
QUICK LINKS
Secure Payment By
Support Hours
We’re here to assist you around the clock, six days a week.
Monday – Friday: 10:00 AM to 6:00 PM
Saturday: 10:00 AM to 3:00 PM
Sunday: Closed
© Copyright 2026 Analystview Market Insights | All Rights Reserved